Key Points
- Director Richard Douglas bought 200,000 shares for $128,000 at $0.64 each, increasing his position by 102.56% to 395,000 shares.
- Aldeyra shares recently traded at $0.64, near their 52-week low of $0.53 and well below the 52-week high of $5.93.
- The company reported a quarterly loss of $0.06 per share, beating analyst expectations of a $0.11 loss. Analyst sentiment was mixed, with a consensus “Hold” rating and a $2.00 price target.
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Get Free Report) Director Richard Douglas purchased 200,000 shares of the firm's stock in a transaction that occurred on Wednesday, November 11th. The shares were acquired at an average cost of $0.64 per share, with a total value of $128,000.00. Following the completion of the purchase, the director directly owned 395,000 shares in the company, valued at $252,800. The trade was a 102.56% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Aldeyra Therapeutics Stock Up 2.2%
ALDX traded up $0.01 during trading hours on Friday, reaching $0.64. 734,135 shares of the company's stock traded hands, compared to its average volume of 867,410. The firm has a 50-day moving average price of $0.97 and a 200 day moving average price of $2.09. Aldeyra Therapeutics, Inc. has a 52-week low of $0.53 and a 52-week high of $5.93. The firm has a market capitalization of $38.86 million, a PE ratio of -2.01 and a beta of 1.32.
Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its earnings results on Thursday, November 5th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.05. Equities analysts predict that Aldeyra Therapeutics, Inc. will post -0.27 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts have recently commented on ALDX shares. Wall Street Zen cut shares of Aldeyra Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. HC Wainwright reiterated a "neutral" rating and set a $2.00 price objective on shares of Aldeyra Therapeutics in a report on Wednesday, September 30th. BTIG Research reiterated a "buy" rating on shares of Aldeyra Therapeutics in a report on Tuesday, September 29th. Finally, Weiss Ratings cut shares of Aldeyra Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Monday, September 14th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $2.00.
View Our Latest Stock Analysis on ALDX
Hedge Funds Weigh In On Aldeyra Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in shares of Aldeyra Therapeutics in the 2nd quarter valued at $2,678,000. Renaissance Technologies LLC raised its position in shares of Aldeyra Therapeutics by 146.6% in the 1st quarter. Renaissance Technologies LLC now owns 863,187 shares of the biotechnology company's stock worth $1,459,000 after acquiring an additional 513,187 shares in the last quarter. GSA Capital Partners LLP bought a new position in shares of Aldeyra Therapeutics in the 2nd quarter worth $1,007,000. Ieq Capital LLC purchased a new stake in shares of Aldeyra Therapeutics during the 2nd quarter worth $440,000. Finally, Palo Alto Investors LP purchased a new stake in shares of Aldeyra Therapeutics during the 2nd quarter worth $331,660. Institutional investors own 59.71% of the company's stock.
About Aldeyra Therapeutics
(
Get Free Report)
Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing treatments for immune-mediated diseases, including conditions affecting the eye. The company's research centers on reactive aldehyde species (RASP), which it aims to inhibit to address inflammation and related disease processes. Aldeyra's investigational medicines include reproxalap, a small-molecule RASP inhibitor studied for ocular conditions such as dry eye disease and allergic conjunctivitis. Its pipeline has also included candidates intended to treat systemic immune-mediated conditions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
